MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy
暂无分享,去创建一个
J. Briones | A. López-Guillermo | L. Colomo | E. Campo | E. González-Barca | T. Cardesa-Salzmann | F. Climent | S. Mercadal | J. Mate | J. Sancho | L. Arenillas | S. Serrano | A. Valera | Antonio Martínez | J. Rovira | I. Espinosa | S. Novelli | O. Salamero | N. Erill | D. Martínez | P. Castillo
[1] A. Rosenwald,et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.
[2] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Benekli,et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab , 2012, Cancer.
[4] R. Spang,et al. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas , 2012, International journal of cancer.
[5] K. Young,et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Monti,et al. Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas , 2012, PloS one.
[7] K. Young,et al. High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma , 2012, The American journal of surgical pathology.
[8] E. Jaffe,et al. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. , 2011, Hematology. American Society of Hematology. Education Program.
[9] A. Ariza,et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas , 2011, Histopathology.
[10] W. Chan,et al. Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOP , 2011, British journal of haematology.
[11] M. Neat,et al. Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience , 2011, Journal of Clinical Pathology.
[12] Elias Campo,et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.
[13] R. Siebert,et al. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Giné,et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. , 2011, Blood.
[15] R. Gascoyne,et al. MYC and Aggressive B-cell Lymphomas , 2011, Advances in anatomic pathology.
[16] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[17] L. Colomo,et al. IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas , 2010, The American journal of surgical pathology.
[18] E. Giné,et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior , 2010, Haematologica.
[19] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Dirk Hasenclever,et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Rimsza,et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma , 2010, Haematologica.
[22] Matija Snuderl,et al. B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.
[23] C. Copie-Bergman,et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[25] I. Miura,et al. Clinical significance of 8q24/c‐MYC translocation in diffuse large B‐cell lymphoma , 2009, Cancer science.
[26] A. Rosenwald,et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.
[27] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[28] A Rosenwald,et al. Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) , 2007, Journal of Clinical Pathology.
[29] S. Yoon,et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type , 2008, Histopathology.
[30] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Richard Simon,et al. Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.
[32] R. Spang,et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.
[33] R. Siebert,et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. , 2006, The Journal of molecular diagnostics : JMD.
[34] G. Flandrin,et al. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis , 2006, Leukemia & lymphoma.
[35] R. Campanini,et al. Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance , 2006, Journal of Translational Medicine.
[36] P. Sonego,et al. Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection? , 2005, Leukemia.
[37] Torsten Hothorn,et al. On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..
[38] Emili Montserrat,et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.
[39] Axel Benner,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.
[40] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[41] D.,et al. Regression Models and Life-Tables , 2022 .